| Payson Care Center | |
| 107 East Lone Pine Drive, Payson, Arizona 85541 | |
| (928) 474-6896 | |
| Name | Payson Care Center |
|---|---|
| Location | 107 East Lone Pine Drive, Payson, Arizona |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 163 |
| Occupancy Rate | 30.55% |
| Medicare ID (CCN) | 035117 |
| Legal Business Name | Payson United Medical Investors Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1033177308 |
| Organization Name | PAYSON UNITED MEDICAL INVESTORS LLC |
| Doing Business As | PAYSON CARE CENTER |
| Address | 107 E Lone Pine St, Payson, AZ 85541 |
| Phone Number | 928-474-6896 |
News Archive
Labopharm Inc. today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year.
A Dutch study that included nearly 90,000 women finds that liquid-based cytology, a commonly used alternative to conventional Pap tests, is not superior to Pap tests for the detection of cervical cancer precursors or cancer, according to a study in the October 28 issue of JAMA.
A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.
QHR Technologies Inc. announced today that it has granted an aggregate of 1,000,000 stock options to various directors, employees and consultants of the Company.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Labopharm Inc. today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year.
A Dutch study that included nearly 90,000 women finds that liquid-based cytology, a commonly used alternative to conventional Pap tests, is not superior to Pap tests for the detection of cervical cancer precursors or cancer, according to a study in the October 28 issue of JAMA.
A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.
QHR Technologies Inc. announced today that it has granted an aggregate of 1,000,000 stock options to various directors, employees and consultants of the Company.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $99788 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 26.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.41 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 28.36 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.13 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.33 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.17 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.04 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 93.02 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.31 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.14 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.39 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 17.52 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.28 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 61.89 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 85.29 | 82.93 |
News Archive
Labopharm Inc. today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year.
A Dutch study that included nearly 90,000 women finds that liquid-based cytology, a commonly used alternative to conventional Pap tests, is not superior to Pap tests for the detection of cervical cancer precursors or cancer, according to a study in the October 28 issue of JAMA.
A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.
QHR Technologies Inc. announced today that it has granted an aggregate of 1,000,000 stock options to various directors, employees and consultants of the Company.
› Verified 4 days ago
Rim Country Health & Retirement Community Location: 807 West Longhorn Road, Payson, Arizona 85541 Phone: (928) 474-1120 |